No Record Found
Sector
PharmaceuticalsOpen
₹201.6Prev. Close
₹201.28Turnover(Lac.)
₹593.77Day's High
₹203.8Day's Low
₹195.1152 Week's High
₹21452 Week's Low
₹49.06Book Value
₹43.48Face Value
₹10Mkt Cap (₹ Cr.)
1,493.47P/E
10.43EPS
19.57Divi. Yield
0No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | 
|---|---|---|---|---|
| Equity Capital | 73.77 | 73.77 | 73.77 | 73.77 | 
| Preference Capital | 0 | 0 | 0 | 0 | 
| Reserves | 138.31 | 129.78 | 122.22 | 110.74 | 
| Net Worth | 212.08 | 203.55 | 195.99 | 184.51 | 
| Minority Interest | 
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 | 
|---|---|---|---|---|
| Revenue | 16.46 | 20.34 | 31.04 | 30.03 | 
| yoy growth (%) | -19.06 | -34.47 | 3.35 | -43.71 | 
| Raw materials | 0 | 0 | 0 | 0 | 
| As % of sales | 0 | 0 | 0 | 0 | 
| Employee costs | -8.57 | -7.75 | -15.81 | -14.62 | 
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 | 
|---|---|---|---|---|
| Profit before tax | 1.38 | 0.51 | 0.62 | 0.89 | 
| Depreciation | -3.43 | -3.44 | -0.66 | -0.63 | 
| Tax paid | 0 | 0.03 | 0.51 | -0.47 | 
| Working capital | -3.05 | -121.58 | 13.22 | -29.74 | 
| Other operating items | 
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 | 
|---|---|---|---|---|
| Growth matrix (%) | ||||
| Revenue growth | -19.06 | -34.47 | 3.35 | -43.71 | 
| Op profit growth | -39.31 | -125.46 | -244.24 | -45.16 | 
| EBIT growth | -1.64 | 41.81 | -10.36 | 0.41 | 
| Net profit growth | 149.2 | -51.05 | 170.09 | -31.49 | 
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | 
|---|---|---|---|---|---|
| Gross Sales | 0 | 0 | 1.97 | 52.4 | 59.4 | 
| Excise Duty | 0 | 0 | 0 | 0 | 0 | 
| Net Sales | 0 | 0 | 1.97 | 52.4 | 59.4 | 
| Other Operating Income | 0 | 0 | 0 | 0 | 0 | 
| Other Income | 41.56 | 37.4 | 42.81 | 30.12 | 6.86 | 
| Company Name | LTP (₹) | P/E  (%) | Mkt.Cap  (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield  (%) | Sales Qtr  (₹.Cr) | Book Value (₹) | 
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,703.4 | 82.06 | 4,08,750.71 | 753.53 | 0.94 | 5,566.68 | 101.44 | 
| Divis Laboratories Ltd DIVISLAB | 6,655 | 75.61 | 1,76,633.5 | 557 | 0.45 | 2,357 | 561.08 | 
| Cipla Ltd CIPLA | 1,540.1 | 23.94 | 1,24,437.16 | 1,210.53 | 1.04 | 4,495.16 | 411.56 | 
| Torrent Pharmaceuticals Ltd TORNTPHARM | 3,602.4 | 61.3 | 1,21,865.35 | 551 | 0.17 | 2,567 | 224.34 | 
| Mankind Pharma Ltd MANKIND | 2,446.6 | 55.79 | 1,00,950.41 | 412.76 | 0 | 2,541.36 | 354.69 | 
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Director & Chief Executive Officer
Sunil Kumar Kalidindi
Non Executive Director
Leona Ambuja
Independent Non Exe. Director
Kalyan Vijay Sivalenka
Non-Executive & Non-Independent Director
Suryanarayana Raju Nandyala
Non Executive Director
Krishna Yeachuri
Independent Director
Uma Garimella
85 Kutchery Road,
Mylapore,
Tamil Nadu - 600004
Tel: 91-44-24616768
Website: http://www.megasoft.com
Email: vivek.kumar@Megasoft.com; srivalli.manda@Megasoft.
Subramanian Building,
1ST Floor No 1, Club House Road,
Chennai - 600002
Tel: 91-44-28462700
Website: www.cameoindia.com
Email: investor@cameoindia.com
Summary
Megasoft Limited is a transnational intellectual property-driven, product-based technology company, which incorporated on 29th June 1999 and focused its expertise on the telecom sector. The Company pr...
Read More
Reports by Megasoft Ltd








 IIFL Customer Care Number
 IIFL Customer Care Number 
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000  / 7039-050-000
 IIFL Capital Services Support WhatsApp Number
 IIFL Capital Services Support WhatsApp Number
+91 9892691696


IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.